Etanercept allergy and anaphylaxis

Journal of Rheumatology

Volumn 39, Issue 11, 2012, Pages 2225-2226

  Quismorio, Anne ^a   Brahmbhatt, Bhaumik ^b   Houng, Mindy ^b   Panush, Richard S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADRENALIN; AZATHIOPRINE; CORTICOSTEROID; DIPHENHYDRAMINE; ETANERCEPT; HYDROXYCHLOROQUINE; IBUPROFEN; METHOTREXATE; MINOCYCLINE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; STEROID;

ADULT; ADULT ONSET STILL DISEASE; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ATOPY; CASE REPORT; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPHAGIA; FACE EDEMA; FEMALE; HUMAN; LETTER; PERIORBITAL EDEMA; PRIORITY JOURNAL; PRURITUS; RHEUMATOID ARTHRITIS; SOYBEAN MILK; TONGUE SWELLING; URTICARIA;

ADULT; ANAPHYLAXIS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; STILL'S DISEASE, ADULT-ONSET; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 84868353395     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120791     Document Type: Letter

References (15)

1. Enbrel® (etancercept) prescribing information. Immunex Corporation, Thousand Oaks, CA. October 2003.
2. Houtman PM, Jansen TL, Blanken R. Anaphylactic reaction in a patient with rheumatoid arthritis: A rare side effect of methotrexate with etanercept as a provoking factor? J Clin Rheumatol 2006;12:321-2.
3. Moore S, Palmer D, Kallarackal G. Beware angioedema with etanercept. Abstract 445. Rheumatology 2008;47:129
4. Sendur OF, Turan Y, Berkit IK, Tastaban E. Angio-oedema in a patient treated with etanercept for rheumatoid arthritis. Basic Clin Pharmacol Toxicol 2009;104:488-90.
5. Puxeddu I, Giori L, Rocchi V, Bazzichi L, Bombardieri S, Tavoni A, et al. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Ann Allergy Asthma Immunol 2012;108:123-4.
6. Kerensky T, Gottlieb A, Yaniv S, Au S. Etanercept: efficacy and safety for approved indications. Expert Opin Biol Ther 2012;11:121-39.
7. Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33:854-61.
8. Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etancercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006;65:379-84.
9. du Pan SM, Dehler S, Curea A, Ziswiler H, Gabay C, Finck A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009;61:560-8.
10. Desai D, Goldbach-Mansky R, Milner JD, Rabin RL, Hull K, Pucino F, et al. Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying drugs. Ann Pharmacother 2009;43:967-72.
11. Abadoglu O, Epozturk K, Atayik E, Kaptanoglu E. Successful rapid rituximab desensitization for hypersensitivity reactions to monoclonal antibodies in a patient with rheumatoid arthritis: A remarkable option. J Invest Allergol Clin Immunol 2011;21:319-21.
12. Bertacini de Moraes J, Aikawa N, de Medeiros Ribeiro A, Saad C, de Carvalho J, Pereira R, et al. Immediate complications of 3,555 injections of anti-TNF alpha. Bras J Rheumatol 2010;50:165-75.
13. Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol 2011;25:549-67.
14. Anderson P, Louie J, Lau A, Broder M. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Curr Rheumatol Rep 2005;7:3-9.
15. Anderson P. Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005;5 Suppl 1:19-22.